NCT03244956 2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
Clinical Trials
15 trialsNCT01723202 2025-08-24
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT03026517 2025-01-23
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02872259 2025-01-14
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Haukeland University Hospital
Phase 1/2 Completed
NCT02392871 2024-11-27
CombiRT
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Completed
NCT03455764 2024-07-31
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02367859 2024-01-30
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Stanford University
Phase 2 Completed
NCT04059224 2023-09-26
TraMel-WT
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT03352947 2020-12-08
INTERIM
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Completed
NCT01682213 2020-05-26
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01713972 2019-03-01
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02296996 2019-01-23
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT01534897 2017-03-15
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
Massachusetts General Hospital
Phase NA Completed
NCT01619774 2016-12-12
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 2 Completed